Briefly noted:

A recent study (SQ Hutsell, M Wu, KT Park. JPGN 2017; 65: 430-31) examined two practice changes with regard to infliximab (IFX) infusions:

1. 1-hour infusions
2. Omission of premedications

The authors reviewed ~900 IFX infusions; though, only 111 infusions were administered without premedications.  These two changes resulted in a 51% decrease in infusion hours, despite a 9% increase in total number infusions. No increase in adverse reactions was identified.

The authors state that these changes improve patient experience, shorten monitoring time, and reduce costs.